CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program
FDA Law Blog
DECEMBER 3, 2023
covered insulin product or vaccine). Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. CMS also provides manufacturers a “special opportunity” to get a preliminary (i.e., state pharmaceutical assistance programs).
105 
Let's personalize your content